Conference Proceeding

Anti-arrhythmic effects of atrial specific IKur block: A simulation study

Sch. of Phys. & Astron., Univ. of Manchester, Manchester, UK
10/2010; pp.429 - 432 In proceeding of: Computing in Cardiology, 2010
Source: IEEE Xplore

ABSTRACT The ultra rapid potassium current (IKur) is an attractive pharmacological target in atrial fibrillation (AF) management due to its atrial specific nature. An experimentally based 78% IKur reduction was incorporated into a human atrial action potential (AP) model under sinus rhythm (SR) and atrial fibrillation (AF) conditions. Its effects on cell and tissue level electrical activity were simulated. IKur block reduced AP duration (APD) and effective refractory period (ERP) under SR conditions, but prolonged APD and ERP under AF conditions. IKur block modulated tissue's ability to sustain high pacing rate conduction under SR and AF conditions. Vulnerability window (VW) was augmented under SR, and reduced under AF conditions. IKur block did not effect on re-entrant waves in 2D and 3D simulations. Simulations show pro-arrhythmic effects in SR, but anti-arrhythmic effects in AF case due to IKur block.

0 0
 · 
0 Bookmarks
 · 
36 Views
  • Article: Evolution, mechanisms, and classification of antiarrhythmic drugs: focus on class III actions.
    [show abstract] [hide abstract]
    ABSTRACT: Since the use of cinchona bark to treat heart palpitations in the 1700s, antiarrhythmic drug therapy has developed with the discovery of new compounds and the identification of ionic, cellular, and tissue mechanisms of action. Classifications have been developed that organize the large amount of information available about antiarrhythmic drugs around groups of compounds with common mechanisms of action. Despite important and well-recognized limitations, antiarrhythmic drug classification is still widely used. In particularly broad use is the system developed by Singh and Vaughan Williams in the early 1970s and subsequently modified by Singh and Hauswirth and by Harrison. This classification divides drug actions into class I for sodium-channel blockade (with subclasses IA, IB and IC), class II for adrenergic antagonism, class III for action-potential prolongation, and class IV for calcium-channel blockade. The development of class I drugs was curtailed when studies showed that potent sodium-channel blockers (particularly IC agents) can increase mortality in patients with active coronary artery disease. The emphasis in drug development shifted to class III agents, but their use has been limited by the risk of ventricular tachyarrhythmia induction associated with QT prolongation. Current research focuses on the development of new class III drugs that may have improved safety by virtue of greater selectivity of action at faster rates (like those of arrhythmia) or for atrial tissue. Alternative approaches include the modification of existing molecules (like amiodarone) to maintain positive properties while removing undesirable ones, and treatments that target development of the arrhythmia substrate instead of the final electrical product.
    The American Journal of Cardiology 12/1999; 84(9A):11R-19R. · 3.37 Impact Factor
  • Article: New insights into the pharmacology of sodium channel blockers.
    European Heart Journal 12/1992; 13 Suppl F:2-13. · 10.48 Impact Factor
  • Article: Pharmacological approaches in the treatment of atrial fibrillation.
    [show abstract] [hide abstract]
    ABSTRACT: Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is associated with substantial cardiovascular morbidity and mortality. The arrhythmia can be initiated and/or maintained by rapidly firing foci, single- and multiple-circuit reentry. Once initiated, AF alters atrial electrical and structural properties (atrial remodeling) in a way that promotes its own maintenance and recurrence and may alter the response to antiarrhythmic drugs. Thus, initial episodes of paroxysmal (self-terminating) AF lengthens to the point where the arrhythmia becomes persistent (requires cardioversion to restore sinus rhythm) and permanent. AF usually requires a trigger for initiation and a favorable electrophysiological and/or anatomical substrate for maintenance. The substrate includes both cardiovascular (coronary artery disease, valvular heart disease, heart failure, hypertension, dilated cardiomyopathy) and non cardiovascular diseases (thyrotoxicosis, pulmonary diseases). Accordingly, the initial step in patients with AF requires a careful assessment of symptoms and identification of underlying reversible triggers and potentially modifiable underlying structural substrate and treat them aggressively. In contrast to other cardiac arrhythmias, antiarrhythmic drugs (ADs) are the mainstay of therapy. Long-term treatment of AF is directed to restore and maintain the sinus rhythm with class I and III ADs (rhythm-control) or to allow AF to persist and ensure that the ventricular rate is controlled (rate-control) with atrioventricular nodal blocking drugs (digoxin, beta-blockers, verapamil, diltiazem) and prevent thromboembolic complications with anticoagulants. However, the long-term efficacy of ADs for preventing AF recurrence is far from ideal, because of limited efficacy (AF recurs in at least one-half of the patients) and potential side effects, particularly proarrhythmia. Thus, the choice of the appropriate AD will depend on the temporal pattern of the arrhythmia, the presence of associated diseases, easy of administration and adverse effects profile, particularly the risk of proarrhythmia. The recent finding that angiotensin converting enzyme inhibitors and beta-blockers reduce the incidence of AF in patients post myocardial infarction with left ventricular dysfunction confirmed the importance of targeting the underlying arrhythmogenic substrate. This review focuses on the mechanisms underlying AF and the mechanism of action and the efficacy and safety profile of the ADs used in the treatment of atrial fibrillation. The advantages and disadvantages of rhythm and rate control, the role pill in a pocket concept and the role of the new ADs are dicussed.
    Current Medicinal Chemistry 02/2004; 11(1):13-28. · 4.86 Impact Factor

Full-text

View
1 Download
Available from

Keywords

3D simulations
 
AF case
 
AF conditions
 
anti-arrhythmic effects
 
AP duration
 
atrial fibrillation
 
atrial specific nature
 
attractive pharmacological target
 
effective refractory period
 
experimentally based 78% I<sub>Kur</sub> reduction
 
human atrial action potential
 
I<sub>Kur</sub> block
 
I<sub>Kur</sub> block modulated tissue's ability
 
pacing rate conduction
 
pro-arrhythmic effects
 
re-entrant waves
 
Simulations
 
tissue level electrical activity
 
ultra rapid potassium current
 
Vulnerability window